English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Department of Medical Oncology Vall d’Hebron University Hospital and VHIO Vall d’Hebron Insitute of Oncology, Barcelona, Spain; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK Correspondence to: Maria Alsina. Department of Medical Oncology Vall d’Hebron University Hospital and VHIO Vall d’Hebron Insitute of Oncology, Passeig de la Vall d’Hebron 119-129, 08035, Barcelona, Spain. Email: malsina@vhio.net. Comment on: Kawazoe A, Yamaguchi K, Yasui H, et al. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. Eur J Cancer 2020;129:97-106.

Safety and preliminary signs of efficacy with the combination of pembrolizumab plus oxaliplatin and S-1 in Japanese gastric cancer patients